Mark N. Stein
About
Mark N. Stein is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Mark N. Stein has authored 243 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Pulmonary and Respiratory Medicine, 134 papers in Oncology and 60 papers in Molecular Biology. Recurrent topics in Mark N. Stein's work include Prostate Cancer Treatment and Research (75 papers), Cancer Immunotherapy and Biomarkers (64 papers) and Renal cell carcinoma treatment (41 papers). Mark N. Stein is often cited by papers focused on Prostate Cancer Treatment and Research (75 papers), Cancer Immunotherapy and Biomarkers (64 papers) and Renal cell carcinoma treatment (41 papers). Mark N. Stein collaborates with scholars based in United States, France and United Kingdom. Mark N. Stein's co-authors include Robert S. DiPaola, Eileen White, Susan Goodin, Kevin Bray, Grace L. Lu‐Yao, Charles G. Drake, Yu‐Hsuan Joni Shao, Simantini Eddy, Dmitri Dvorzhinski and Amit Mehta and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Nature Communications.
In The Last Decade
Mark N. Stein
232 papers receiving 5.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mark N. Stein United States | 40 | 2.5k | 2.3k | 2.1k | 1.3k | 992 | 243 | 5.8k | ||
| Young Kwang Chae United States | 40 | 3.1k 1.2× | 2.6k 1.1× | 1.9k 0.9× | 1.7k 1.3× | 777 0.8× | 274 | 6.4k | ||
| Jianping Xiong China | 36 | 2.0k 0.8× | 2.1k 0.9× | 1.6k 0.8× | 1.3k 1.0× | 772 0.8× | 189 | 5.0k | ||
| Davide Melisi Italy | 42 | 3.5k 1.4× | 2.4k 1.0× | 1.3k 0.6× | 1.4k 1.1× | 1.6k 1.6× | 164 | 5.9k | ||
| Chao-Nan Qian China | 41 | 1.9k 0.8× | 2.6k 1.1× | 1.1k 0.5× | 1.6k 1.2× | 758 0.8× | 101 | 5.2k | ||
| Kenji Sugio Japan | 47 | 3.2k 1.3× | 2.7k 1.2× | 3.3k 1.6× | 1.1k 0.9× | 915 0.9× | 276 | 7.1k | ||
| Michael J. Pishvaian United States | 40 | 3.8k 1.5× | 1.9k 0.8× | 1.1k 0.5× | 1.5k 1.1× | 747 0.8× | 216 | 5.8k | ||
| Ferry A.L.M. Eskens Netherlands | 43 | 2.9k 1.2× | 2.6k 1.1× | 1.5k 0.7× | 1.2k 0.9× | 592 0.6× | 161 | 6.4k | ||
| Begoña Mellado Spain | 36 | 1.9k 0.8× | 2.0k 0.8× | 2.2k 1.0× | 1.1k 0.9× | 947 1.0× | 180 | 4.7k | ||
| Maurizio Martini Italy | 44 | 1.9k 0.8× | 2.3k 1.0× | 1.1k 0.5× | 1.3k 1.0× | 1.0k 1.0× | 281 | 6.5k | ||
| Helen Mackay Canada | 41 | 2.9k 1.1× | 2.9k 1.2× | 1.2k 0.6× | 1.3k 1.0× | 787 0.8× | 185 | 7.1k |
Countries citing papers authored by Mark N. Stein
Since
Specialization
Citations
This map shows the geographic impact of Mark N. Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark N. Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark N. Stein more than expected).
Fields of papers citing papers by Mark N. Stein
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mark N. Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark N. Stein. The network helps show where Mark N. Stein may publish in the future.
Co-authorship network of co-authors of Mark N. Stein
This figure shows the co-authorship network connecting the top 25 collaborators of Mark N. Stein. A scholar is included among the top collaborators of Mark N. Stein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark N. Stein. Mark N. Stein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Autio, Karen A., Michael T. Schweizer, Rajendra Chaudhary, et al.. (2025). 2385MO Translational analyses of T cell phenotypes and their association with clinical efficacy in the first-in-human (FIH) trial of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 36. S1212–S1212.
2.
Stein, Mark N., et al.. (2025). Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report. Frontiers in Oncology. 15. 1543622–1543622.
3.
Luke, Jason J., Randy F. Sweis, J. Randolph Hecht, et al.. (2025). Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research. 31(7). 1233–1242.
4.
Atkins, Michael B., Opeyemi A. Jegede, Naomi B. Haas, et al.. (2023). Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal for ImmunoTherapy of Cancer. 11(3). e004780–e004780.
5.
Bupathi, Manojkumar, Siwen Hu‐Lieskovan, Sarina A. Piha‐Paul, et al.. (2023). 764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors. SHILAP Revista de lepidopterología. A859–A859.
6.
Stein, Mark N., Lawrence Fong, Ronald Tutrone, et al.. (2022). ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study. The Oncologist. 27(6). 453–461.
7.
Kim, Isaac Yi, Thomas L. Jang, Sinae Kim, et al.. (2021). Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine. 10(22). 7909–7920.
8.
Tan, Xiang‐Lin, E Jian‐Yu, Yong Lin, et al.. (2020). Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer. Cancer Medicine. 9(7). 2379–2389.
9.
Haas, Naomi B., Leonard J. Appleman, Mark N. Stein, et al.. (2019). Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma. Clinical Cancer Research. 25(7). 2080–2087.
10.
Ferrari, Anna C., Joshi J. Alumkal, Mark N. Stein, et al.. (2018). Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. Clinical Cancer Research. 25(1). 52–63.
11.
Tarapore, Rohinton S., Sachin R. Jhawar, Mark N. Stein, et al.. (2018). ONC201 IN COMBINATION WITH RADIATION EXHIBITS SYNERGISTIC EFFICACY IN HIGH GRADE GLIOMAS AND OTHER ADVANCED CANCERS. Neuro-Oncology. 20. 72–72.
12.
Parikh, Rahul R., Sinae Kim, Mark N. Stein, et al.. (2017). Trends in active surveillance for very low‐risk prostate cancer: do guidelines influence modern practice?. Cancer Medicine. 6(10). 2410–2418.
13.
Bansal, Nitu, Monica Bartucci, Shamila Yusuff, et al.. (2016). BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer. Clinical Cancer Research. 22(24). 6176–6191.
14.
Cosimo, Serena Di, Sriram Sathyanarayanan, Johanna C. Bendell, et al.. (2014). Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. Clinical Cancer Research. 21(1). 49–59.
15.
Shao, Yu‐Hsuan Joni, Dirk F. Moore, Weichung Joe Shih, et al.. (2013). Cancer-specific Survival After Metastasis Following Primary Radical Prostatectomy Compared with Radiation Therapy in Prostate Cancer Patients: Results of a Population-based, Propensity Score–Matched Analysis. European Urology. 65(4). 693–700.
16.
Raez, Luis E., Kyriakos P. Papadopoulos, Alejandro D. Ricart, et al.. (2012). A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 71(2). 523–530.
17.
Shao, Yu‐Hsuan Joni, Kitaw Demissie, Weichung Joe Shih, et al.. (2009). Contemporary Risk Profile of Prostate Cancer in the United States. JNCI Journal of the National Cancer Institute. 101(18). 1280–1283.
18.
Rodón, Jordi, Amita Patnaik, Mark N. Stein, et al.. (2007). A phase I study of q3W R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors. Molecular Cancer Therapeutics. 6.
19.
Ross, Robert W., Ramaprasad Srinivasan, Ulka N. Vaishampayan, et al.. (2007). A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC).. Molecular Cancer Therapeutics. 6.
20.
Stein, Mark N., et al.. (2006). Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling.. PubMed. 26(3A). 1759–63.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Young Kwang Chae Breakdown of academic impact, for papers by Jianping Xiong Breakdown of academic impact, for papers by Davide Melisi Breakdown of academic impact, for papers by Chao-Nan Qian Breakdown of academic impact, for papers by Kenji Sugio Breakdown of academic impact, for papers by Michael J. Pishvaian Breakdown of academic impact, for papers by Ferry A.L.M. Eskens Breakdown of academic impact, for papers by Begoña Mellado Breakdown of academic impact, for papers by Maurizio Martini Breakdown of academic impact, for papers by Helen Mackay